Fundz

Watching Lakewood-Amedex Biotherapeutics Inc.? See every signal: funding, hires, M&A, contracts, sentiment.

Book a demoChoose your plan
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →
Back to SEC Filings
Reg FD DisclosureItem 7.01 · 8-KLOW RiskPositive

Lakewood-Amedex Biotherapeutics Inc.

Filed: Jul 15, 2026CIK: 0002079272
View on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Lakewood-Amedex Biotherapeutics announced the launch of Nu-3, a topically delivered antimicrobial gel for treating infected diabetic foot ulcers, supported by preclinical and clinical data and backed by the company's intellectual property portfolio in drug-resistant infection treatment.

Key Takeaways

Nu-3 is the company's lead program targeting infected diabetic foot ulcers, a significant unmet medical need with serious patient risks

The product launch is supported by extensive preclinical and clinical data demonstrating efficacy

2 more takeaways

Filing Overview

Form Type8-K
Filing DateJul 15, 2026
Item7.01
CategoryReg FD Disclosure
CIK0002079272
Accession #0002079272
Risk LevelLOW
SentimentPositive
Signalopportunity
Topics
product launchregulatory

What This Means

The company is making a public disclosure under Regulation FD, often sharing material information to ensure equal access.
View Full Filing on SEC.govBrowse More Filings

Lakewood-Amedex Biotherapeutics Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.